The Main purpose of this Study was to obtain stable, well-characterized solid dispersions (SDs) of amorphous probucol and polyvinylpyrrolidone K-30 (PVP-K30) with improved dissolution rates. A secondary aim was to investigate the flow-through dissolution method for in-vitro dissolution measurements of small-sized amorphous powders dispersed in a hydrophilic polymer. SDs were prepared by spray drying Solutions of probucol and different amounts of PVP-K30. The obtained SDs were characterized by dissolution rate measurements in a flow-through apparatus, X-ray Powder Diffraction (XRPD), Differential Scanning Calorimetry (DSC), Scanning Electron Microscopy (SEM), particle sizing (laser diffraction) and Brunauer-Emmett-Teller Method (BET) and results were compared with starting material and a physical mixture. The physical stability was monitored after storage at 25 degrees C and 60% RH for up to 12 weeks. The flow-through method was found suitable as dissolution method. All SDs showed improved in-vitro dissolution rates when compared to starting material and physical mixtures. The greatest improvement in the in-vitro dissolution rate was observed for the highest polymer to drug ratio. By means of the results from XRPD and DSC, it was argued that the presence of amorphous probucol improved the dissolution rate, but the amorphous state Could not fully account for the difference in dissolution profiles between the SDs. It was suggested that the increase in surface area due to the reduction in particle size contributed to an increased dissolution rate as well as the presence of PVP-K30 by preventing aggregation and drug re-crystallization and by improving wettability during dissolution. The stabilizing effect of the polymer was verified in the solid state, as all the SDs retained probucol in the amorphous state throughout the entire length of the stability study.
机构:
Univ Lisbon, iMed Res Inst Med & Pharmaceut Sci, Fac Pharm, P-1649003 Lisbon, Portugal
Hovione Farmaciencia SA, R&D Drug Prod Dev, P-2674506 Sete Casas, Loures, PortugalUniv Lisbon, iMed Res Inst Med & Pharmaceut Sci, Fac Pharm, P-1649003 Lisbon, Portugal
Duarte, Iris
Santos, Jose Luis
论文数: 0引用数: 0
h-index: 0
机构:
Hovione Farmaciencia SA, R&D Drug Prod Dev, P-2674506 Sete Casas, Loures, PortugalUniv Lisbon, iMed Res Inst Med & Pharmaceut Sci, Fac Pharm, P-1649003 Lisbon, Portugal
Santos, Jose Luis
Pinto, Joao F.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Lisbon, iMed Res Inst Med & Pharmaceut Sci, Fac Pharm, P-1649003 Lisbon, PortugalUniv Lisbon, iMed Res Inst Med & Pharmaceut Sci, Fac Pharm, P-1649003 Lisbon, Portugal
Pinto, Joao F.
Temtem, Marcio
论文数: 0引用数: 0
h-index: 0
机构:
Hovione Farmaciencia SA, R&D Drug Prod Dev, P-2674506 Sete Casas, Loures, PortugalUniv Lisbon, iMed Res Inst Med & Pharmaceut Sci, Fac Pharm, P-1649003 Lisbon, Portugal
机构:
GlaxoSmithKline Plc, Prod Dev, Collegeville, PA 19426 USA
Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USAGlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USA
Patel, Jagdishwar R.
Carlton, Robert A.
论文数: 0引用数: 0
h-index: 0
机构:
GlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USAGlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USA
Carlton, Robert A.
Yuniatine, Fnu
论文数: 0引用数: 0
h-index: 0
机构:
GlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USAGlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USA
Yuniatine, Fnu
Needham, Thomas E.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USAGlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USA
Needham, Thomas E.
Wu, Lianming
论文数: 0引用数: 0
h-index: 0
机构:
GlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USAGlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USA
Wu, Lianming
Vogt, Frederick G.
论文数: 0引用数: 0
h-index: 0
机构:
GlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USAGlaxoSmithKline Plc, Prod Dev, King Of Prussia, PA 19406 USA